n.a. (TBRA)

0.00
NASDAQ
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NASDAQ
Div & Yield N.A. (N.A)
Allergan Hints It Is Ready to Make a Splash for More Near-term Growth

Allergan Hints It Is Ready to Make a Splash for More Near-term Growth

CEO Brent Saunders plans to reward shareholders after striking a slew of R&D acquisitions in the latter half of 2016.

Allergan Needs a Shot of Investor Confidence

Allergan Needs a Shot of Investor Confidence

Jim Cramer bought this stock for his charitable portfolio. Should you?

Invest in Allergan on Weakness, Analysts Say

Invest in Allergan on Weakness, Analysts Say

Pharmaceutical giant Allergan looks poised to have a great year in 2017.

Tobira Therapeutics Announces Late-Breaking Oral Presentation Of CENTAUR Phase 2b Trial Results At The American Academy For The Study Of Liver Diseases Annual Meeting

Tobira Therapeutics Announces Late-Breaking Oral Presentation Of CENTAUR Phase 2b Trial Results At The American Academy For The Study Of Liver Diseases Annual Meeting

Tobira Therapeutics, Inc. (NASDAQ: TBRA), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for non-alcoholic steatohepatitis (NASH) and other liver diseases, today announced the...

Controversy Over Allergan's 500% Premium for Tobira Looks Overdone

Controversy Over Allergan's 500% Premium for Tobira Looks Overdone

Concern over the steep premium paid for Tobira has been reflected in the public markets, but followers of Allergan say investors reacted too negatively.

Tobira Therapeutics Announces Presentations Related To Cenicriviroc's Development Program In NASH At The American Academy For The Study Of Liver Diseases Annual Meeting

Tobira Therapeutics Announces Presentations Related To Cenicriviroc's Development Program In NASH At The American Academy For The Study Of Liver Diseases Annual Meeting

Tobira Therapeutics, Inc. (NASDAQ:TBRA), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for non-alcoholic steatohepatitis (NASH) and other liver diseases, today announced...

Jim Cramer's Top Takeaways: Flex, Walt Disney, Allergan

Jim Cramer's Top Takeaways: Flex, Walt Disney, Allergan

Cramer's a big fan of Flex' technology and says Walt Disney may look like a dog now but it will soon have its day.

Jim Cramer's 'Mad Money' Recap: Just Buy What's Working

Jim Cramer's 'Mad Money' Recap: Just Buy What's Working

Some companies have powerful trends to bolster their numbers, Fed or no Fed, Cramer says.

Allergan's Boldness may not be Limited to Tobira Deal

Allergan's Boldness may not be Limited to Tobira Deal

The Irish drugmaker isn't likely done making deals, even though it just made two, and it could take a look at Alder Biopharmaceuticals next, analysts believe.

TBRA SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Tobira Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information

TBRA SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Tobira Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information

The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Tobira...

Stocks Hold Higher as Fed's Yellen Says Economy Picking Up

Stocks Hold Higher as Fed's Yellen Says Economy Picking Up

Stocks add to gains on Wednesday afternoon after the Federal Reserve opts to leaves rates unchanged at its September meeting.

INVESTOR ALERT: Levi & Korsinsky, LLP Announces An Investigation Into Whether The Sale Of Tobira Therapeutics, Inc. To Allergan Plc For $28.35 Per Share Is Fair To Shareholders

INVESTOR ALERT: Levi & Korsinsky, LLP Announces An Investigation Into Whether The Sale Of Tobira Therapeutics, Inc. To Allergan Plc For $28.35 Per Share Is Fair To Shareholders

The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Tobira Therapeutics, Inc.

Stocks Hold Higher in Wait for Fed, Crude Jumps on Supply Drop

Stocks Hold Higher in Wait for Fed, Crude Jumps on Supply Drop

Stocks hold higher on Wednesday as investors await a policy decision from the Federal Reserve.

Tobira Therapeutics Reaches Analyst Target Price

Tobira Therapeutics Reaches Analyst Target Price

In recent trading, shares of Tobira Therapeutics Inc have crossed above the average analyst 12-month target price of $19.00, changing hands for $38.91/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Stock Futures Rise as Bank of Japan Tackles Deflation

Stock Futures Rise as Bank of Japan Tackles Deflation

Stock futures climb after the Bank of Japan makes moves to tackle deflation, while U.S. investors await a policy decision from their own central bank.

Jim Cramer's 'Mad Money' Recap: This Market Is Driving Me Mad!

Jim Cramer's 'Mad Money' Recap: This Market Is Driving Me Mad!

Gains from one day are being wiped out the next and vice versa, Cramer says.

Wall Street Creeps Higher Ahead of Fed Decision

Wall Street Creeps Higher Ahead of Fed Decision

Wall Street makes few big moves on Tuesday as investors opt to sit on the sidelines ahead of a major day of monetary policy news.

Cramer: What a Revoltin' Market Development This Is

Cramer: What a Revoltin' Market Development This Is

Stocks rally and then get smacked down in this inconsistent atmosphere.

Stocks Post Modest Gains as Fed Meets, Crude Higher

Stocks Post Modest Gains as Fed Meets, Crude Higher

Stocks move slightly higher Tuesday as nerves peak over how the Federal Reserve and the Bank of Japan will vote in their separate two-day meetings.

Jim Cramer: Allergan Deal Looks Like an Overpay

Jim Cramer: Allergan Deal Looks Like an Overpay

Jim Cramer believes Allergan paid too much for Tobira unless CEO Brent Saunders can prove that he knows something about the company that other market participants do not.

Stocks Rise as Wall Street Looks to Fed's Decision on Interest Rates

Stocks Rise as Wall Street Looks to Fed's Decision on Interest Rates

Stocks are higher Tuesday as Federal Open Market Committee members convene for their widely anticipated meeting.

These Biotech Names Are on My Radar

These Biotech Names Are on My Radar

But I'm expecting that things will slow into the Fed news.

Tobira Therapeutics (TBRA) Stock Surging After Allergan Deal

Tobira Therapeutics (TBRA) Stock Surging After Allergan Deal

Tobira Therapeutics (TBRA) will be acquired by Allergan for about $1.7 billion.

Stock Futures Hold Higher as Housing Starts Slow

Stock Futures Hold Higher as Housing Starts Slow

Stock futures move higher on Tuesday as Federal Open Market Committee members convene for their widely anticipated meeting.

Tobira Therapeutics Announces Initiation Of Phase 1 Combination Study Of Cenicriviroc And Evogliptin

Tobira Therapeutics Announces Initiation Of Phase 1 Combination Study Of Cenicriviroc And Evogliptin

Tobira Therapeutics, Inc. (NASDAQ:TBRA), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for non-alcoholic steatohepatitis (NASH) and other liver diseases, today announced the...

Tobira Therapeutics Announces Appointment Of Dr. Laurent Fischer As Industry Co-chair Of The Liver Forum Steering Committee

Tobira Therapeutics Announces Appointment Of Dr. Laurent Fischer As Industry Co-chair Of The Liver Forum Steering Committee

Tobira Therapeutics, Inc. (NASDAQ:TBRA), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for non-alcoholic steatohepatitis (NASH) and other liver diseases, today announced that...

Tobira Therapeutics To Participate In Two Conferences In September

Tobira Therapeutics To Participate In Two Conferences In September

Tobira Therapeutics, Inc. (NASDAQ:TBRA) today announced that company management will present an overview of the company at the following conferences in September.

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

Here's a technical look at five under-$10 stocks that look poised to trade higher from current levels.

Tobira Therapeutics Reports Second Quarter 2016 Financial And Business Results

Tobira Therapeutics Reports Second Quarter 2016 Financial And Business Results

Tobira Therapeutics, Inc. (NASDAQ: TBRA) a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for non-alcoholic steatohepatitis (NASH) and other liver diseases, today reported...